ERYTECH Pharma S.A.
Develops red blood cell-based therapies for cancer and orphan diseases.
ERYP | PA
Overview
Corporate Details
- ISIN(s):
- FR0010417360 (+2 more)
- LEI:
- 969500U8ZZCODU8A9374
- Country:
- France
- Address:
- 60 AVENUE ROCKEFELLER, 69008 LYON
- Website:
- https://phaxiam.com/
- Sector:
- Manufacturing
Description
ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company that develops innovative therapeutics based on its proprietary ERYCAPS platform, which encapsulates drug substances inside red blood cells. This technology is designed to improve the efficacy and safety of treatments by prolonging the drug's circulation time and reducing side effects. The company's primary focus is on developing treatments for severe forms of cancer and orphan diseases. Its lead product candidate, eryaspase, encapsulates the enzyme L-asparaginase to starve cancer cells of essential nutrients, targeting indications such as acute lymphoblastic leukemia and pancreatic cancer.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-06-28 22:05 |
Phaxiam Therapeutics announces its new mnemonic code on Euronext and Nasdaq: PH…
|
English | 139.1 KB | ||
| 2023-06-27 18:00 |
Information mensuelle relative au nombre total de droits de vote et d’actions c…
|
French | 203.4 KB | ||
| 2023-06-27 18:00 |
Monthly information related to total number of voting rights and shares composi…
|
English | 222.6 KB | ||
| 2023-06-26 22:05 |
ERYTECH et PHERECYDES annoncent leur fusion pour former PHAXIAM Therapeutics
|
French | 267.2 KB | ||
| 2023-06-26 22:05 |
ERYTECH and PHERECYDES announce merger and name change to PHAXIAM Therapeutics
|
English | 262.4 KB | ||
| 2023-06-23 22:30 |
ERYTECH annonce l'approbation de la fusion avec Pherecydes et communique les ré…
|
French | 274.4 KB | ||
| 2023-06-23 22:30 |
ERYTECH announces the approval of the merger with Pherecydes and reports the re…
|
English | 277.3 KB | ||
| 2023-06-21 18:00 |
AKKADIAN PARTNERS DOES NOT INTEND TO PARTICIPATE IN ERYTECH'S GENERAL MEETING O…
|
English | 165.2 KB | ||
| 2023-06-20 22:05 |
ERYTECH annonce qu'Akkadian poursuit sa tentative de déstabilisation avec l'int…
|
French | 206.7 KB | ||
| 2023-06-20 22:05 |
ERYTECH announces that Akkadian is continuing its attempt at destabilization wi…
|
English | 259.8 KB | ||
| 2023-06-15 08:35 |
AKKADIAN PARTNERS SECURES THE APPOINTMENT OF A LEGAL EXPERT - AND REQUESTS CALL…
|
English | 158.3 KB | ||
| 2023-06-15 07:30 |
AKKADIAN PARTNERS OBTIENT LA NOMINATION D'UN EXPERT JUDICIAIRE - ET INVITE ERYT…
|
French | 181.4 KB | ||
| 2023-06-14 20:00 |
ERYTECH annonce que le tribunal de commerce a débouté Akkadian de sa demande de…
|
French | 172.4 KB | ||
| 2023-06-14 20:00 |
ERYTECH announces that the Commercial Court has rejected Akkadian's request to …
|
English | 231.5 KB | ||
| 2023-06-13 18:00 |
Information mensuelle relative au nombre total de droits de vote et d’actions c…
|
French | 215.3 KB |
Automate Your Workflow. Get a real-time feed of all ERYTECH Pharma S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ERYTECH Pharma S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ERYTECH Pharma S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-06-23 | N/A | Other | Other | 3,697,533 | 2,255,495.13 EUR |
| 2023-06-23 | N/A | Other | Other | 71,839 | 43,821.79 EUR |
| 2023-06-23 | N/A | Other | Other | 54,862 | 33,465.82 EUR |
Peer Companies
